Quisinostat (USAN;[2] development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity.[3][4][5] It is highly potent against class I and II HDACs.[6]
Clinical data | |
---|---|
Other names | JNJ-26481585 |
ATC code |
|
Pharmacokinetic data | |
Bioavailability | oral[1] |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C21H26N6O2 |
Molar mass | 394.479 g·mol−1 |
3D model (JSmol) |
|
| |
|
It was developed by Janssen Pharmaceuticals and licensed to NewVac LLC.[7]
Preclinical studies show that quisinostat amplifies HDAC-repressed expression of E-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells.[7]
Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.[8]